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Abstract
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Zusammenfassung
Eine sichere, effektive und risikoreduzierte parenterale Ernährung (PE)
hat sich in Form der All-In-One-Ernährung (AIO-Ernährung) für praktisch
alle Indikationen und Anwendungen etabliert. Bei PE werden Wasser,
Energie (Kohlenhydrate und Fett), Aminosäuren, Vitamine und Spuren-
elementen gemeinsam infundiert, entweder mit industriell gefertigten
Standard-AIO-Zwei-oderDreikammerbeuteln(HaltbarkeitistinderRegel
>12 Monate) komplettiert mit Elektrolyten oder Mikronährstoffen, wo
dies geeignet ist, oder mit individuell gemischten anwendungsbereiten
AIO-Nährmischungen (Compounding, Herstellung in der Regel täglich
oderwöchentlichundKühllagerungbei2–8°C).Diephysikochemische
und mikrobiologische Stabilität von AIO-Mischung ist entscheidend für
die Sicherheit und Wirksamkeit einer patientenspezifischen PE und er-
fordert auch für die Qualitätssicherung pharmazeutisches Fachwissen.
Die Stabilität muss für eine Applikationsdauer von 24 (–48) Stunden
dokumentiert werden. Sinnvoll ist eine begrenzte Zahl an PE-Regimen
imeinzelnenKrankenhaus.UmdieArzneimittel-undMedikationssicher-
heit zu gewährleisten ist die korrekte Beschriftung von patientenspezi-
fisch vorbereiteten PE Mischungen notwendig. Die Vorgaben zur Aufbe-
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werden.EinMonitoringistnotwendig.Mikronährstoffesollengrundsätz-
lichgetrenntvonAIO-Mischungenverabreichtwerden.Spurenelemente
und/oder Kombinationspräparate wasserlöslicher bzw. wasserlösli-
cher/fettlöslicher Vitaminpräparate Mischungen dürfen bei dokumen-
tierterKompatibilitätundStabilitätzurPEauchzugespritztwerdenunter
Beachtung strenger Asepsis. AIO-Mischungen sollten in der Regel nicht
als Träger für Medikamente verwendet werden (Inkompatibilitäten).
Schlüsselwörter: Infusionssysteme, Compounding, industrielle PE-
Systeme, Stabilität, Qualitätssicherung
All-in-one (AIO) admixtures
Definition and significance of AIO
admixtures
• Water,energy(carbohydratesandlipids),aminoacids,
vitaminsandtraceelementsareinfusedtogetherwith
parenteral nutrition (PN) (B).
• All-in-one admixtures (AIO-admixtures) provide safe,
effective and low-risk PN for practically all indications
and applications (B).
Commentary
Infusion systems
Infusion systems for the administration of PN comprise
of:
• Individualsubstrates(carbohydrates,lipidsandamino
acids)administeredwithseparatebottles(multi-bottle
system/modular system).
• Combination solutions (carbohydrate/amino acid
mixtures) with separate administration of lipids.
• AIO admixtures where the substrates (carbohydrates,
lipids, amino acids, electrolytes and micronutrients)
are admixed in a single container and simultaneously
administered through one intravenous line (“all-in-
one”).Ideally,allsubstratesareadministeredtogether,
taking compatibility and stability of the components
andtheadmixtureintoaccountandlimitingparticulate
matter. This system results in reduced manipulation
andsavingsofmaterial,timeandpersonnelworkload.
AIO admixtures require only one intravenous line, and
the risk of infection is lowered by the closed system.
The complete and simultaneous administration of all
substrates reduces the risk for metabolic complica-
tions. AIO admixtures offer a convenient system for
patients, clinicians and nursing staff.
AIO admixtures
AIO admixtures may be obtained by two different ways:
• Industrially-manufactured standard AIO provided as
two- or three-chamber bags: In case of a two-chamber
bag, a lipid emulsion is admixed with a transfer set
shortly before its administration to the patient, thus
creating an AIO admixture. Three-chamber bags con-
tain all the macronutrients and electrolytes in three
separate compartments. The substrates are mixed
together immediately prior to intravenous application
by breaking the separation seals between the bag
chambers. Vitamins and trace elements are injected
into the bag prior to administration or infused by a
separate intravenous line. When not mixed together,
these standard multi-chamber bags have usually a
shelf life of more than 12 months.
• Individually admixed AIO admixtures (compounding):
These allow for the provision of patient-specific ready-
to-use admixtures, individually adapted according to
energy, volume and substrate needs. These are
aseptically manufactured from various components,
usually in hospital pharmacies, and are designed for
immediateintravenousadministration,withnomixing
or admixing required prior to administration. These
bags are usually manufactured on either a daily or
weekly basis due to their limited stability. They require
storage at 2–8°C.
Bothapproachesrequireaseptictechniquesofhandling,
because it is not possible to sterilise an AIO admixture
after ready-to-use completion [1].
Significance
AIO systems in PN provide microbiological and metabolic
advantages as well as benefits in handling and compati-
bility, as compared to the use of individual components
or combination solutions [2], [3], [4], [5], [6], [7], [8].
Theuseofstandardisedparenteraladmixturessimplifies
prescription, compounding and reduces complications.
In addition, it improves patient safety and efficiency of
treatment [6], [9].
A cost-benefit analysis by Durand-Zaleski et al. [3] com-
pared the costs and financial benefits of multi-bottle
systems with an AIO system. The expenditure included
the costs for compounding, substrates and equipment.
Financialbenefitswereestimatedfromreductionincosts
due to prevented infections (especially catheter-related
infections)andreductioninrisksduetotheuseofanAIO
system. Frei et al. [5] took into consideration the costs
formaterialrequired(bottles,bags,substrates,etc.),tests
(laboratory) and staffing. A two-chamber bag together
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AIO system. Although the multi-bottle system was more
economical, the total daily cost was lower when the two-
chamber bag system was used.
Quality assurance is an important aspect of PN therapy.
Increased manipulations during PN raise the frequency
of nosocomial infections [10], [11], [12]. This risk is
higher with multi-bottle systems due to an increased fre-
quency of manipulation and the necessary admixing into
bottles. Durand-Zaleski et al. [3] showed a reduction in
nosocomial infections with using an AIO system, which
resulted in overall savings due to elimination of sub-
sequent expenses.
An AIO admixture comprises 50 or more components in
aready-to-usebag,andrepresentsanextremelycomplex
pharmaceuticalformulation.GoodManufacturingPractice
(GMP) is a quality standard (materials, room conditions,
equipment,employees(training),processes,documenta-
tion,distributionetc.)thatmustbefollowedformanufac-
turing AIO admixtures [13], [14], [15]. PN preparations
must be [16]:
• therapeutically and pharmaceutically suitable for the
patient
• free of microbiological impurities and pyrogens
• correctly dosed and admixed (proven compatibility)
• correctly labelled, stored and administered.
Total complete admixtures which are true ready-to-use
PN are not yet commercially available due to physico-
chemical instabilities. Adaptation of AIO admixtures to
meetindividualrequirementsmustbepreparedinaccord-
ance to specific pharmaceutical manufacturing regula-
tionsandstrictasepticconditions[17],[18]ateverystep.
The evaluation of microbiological (aseptic preparation)
and physico-chemical stability (emulsion dispersion,
solubility, decomposition, sorption phenomena etc.) re-
quires specialised pharmaceutical knowledge [18], [19].
These parameters influence the quality of PN [20].
Standardisation is a sensible option in PN, when balan-
cing requirements and simplification of treatment, but
individual regimens are also needed to meet specific re-
quirements,e.g.ininfantsandchildren,long-term(home)
PN, etc. [21]. Industrially-prepared multi-chamber bags,
with established standard compositions, often are an
attractivemethodofprovidingPN.Theyarepredominantly
used in the short-term PN-treatment of hospitalised
adults.Individualcompoundingis,however,stillrequired
[22]. Industrial multi-chamber bags allow the admixing
of the stable components in a closed system (asepsis)
directlybeforeadministration.Multi-layerplasticcontain-
ers enable long-term storage of the compartmented
components(reductionofoxygenpermeationinoxidation-
sensitive components [23]; cover wrapping with oxygen
absorbers further increase this stability). Glucose and
amino acids are separated in two-chamber bags so that
Maillard reactions (browning) are prevented; the lipid
component, which is normally critical for the overall sta-
bility(fatdropletdistribution),isadmixedtotheremaining
AIO admixture. Addition of electrolytes, trace elements
or vitamins into the AIO admixture must follow GMP
standards and the compatibility of the components
(controlled conditions, documentation) must be ensured
[13], [14], [15], [16].
If further admixing is required (e.g. special amino acids
such as glutamine; lipids such as LCT, LCT/MCT, special
fatty acid compositions, or electrolytes such as phos-
phate, magnesium or calcium), these should be individu-
allyadmixed.Cost-benefitanalysesofmulti-chamberbags
ascomparedtoindividualcompoundingshouldincorpor-
ate the effectiveness and rational for PN use. The
presentlyavailablestudiesaddressingthistopicareeither
very basic or are outdated [6], [20], [24]. Local specifica-
tionsandrequirementsshoulddecidewhetherindividual
compounding or commercial multi-chamber bags are
used for administration of PN.
Logistics, stability
Role of the pharmacist in the nutrition
team in PN
• Close collaboration between a pharmacist and the
multidisciplinary nutrition support team is rec-
ommended; the extent of such collaboration will de-
pend on the pharmacist’s specific skills, standard of
knowledge in clinical nutrition and experience in (clin-
ical) pharmacy practice (C).
Commentary
Areasofpharmaceuticalcarewithinthenutritionsupport
team are [25], [26], [27]:
• Transfer of pharmaceutical knowledge on products
and equipment used for PN.
• Potential interactions or incompatibilities between
componentsandotheradministeredadmixtures/medi-
cines, and their prevention.
• Providing instructions regarding the stability of PN re-
gimesandtheircorrecthandling(storage,lightprotec-
tion, administration, etc.).
• Checking the patient-specific prescriptions of admix-
tures, their preparation and concomitant drugs.
• Advisoryfunctionregardingtheselection,composition
and administration of PN as well as further additions
in hospital patient and patients discharged on home
PN.
• Advising on drug-related problems or observations:
admixing, stability, incompatibility, bioavailability,
documentation/clarification of adverse reactions to
drugs.
• Providing an insight into measures to increase drug
safety (evidence-based medicine/pharmacy).
• Supportinintegrationandstandardisationoftreatment
regimens, including suggestions for therapeutic
strategies.
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ents.
• Support of education and training.
• Co-operationinqualityassuranceandqualityimprove-
ment by means of establishing medical and nursing
standards as well as monitoring.
Preparation and manufacturing
regulations
Strict requirements and conditions for compounding the
all-in-oneadmixturesarerequiredbecauseitisimpossible
to sterilise the end product, and because of the large
number of components with potential physico-chemical
incompatibilitiesandinstabilities(o/wemulsionsystems
with potential admixture of drugs) [17], [28], [29], [30].
The compatibility of the individual components, and the
pH and homogeneity of the emulsion need to be tested,
and a weight control inspection of mass (target/actual
check) be carried out. The maximum amount of selected
components tested as being compatible (or which are
knowntobecompatibleaccordingtoliteratureresearch),
must be established. It is essential to work under strict
asepticconditions.Thisrequiresthenecessarypremises
(laminar airflow benches, clean rooms, defined air
turnover, compounding machines), the validation of the
manufacturingprocesswithsuitablemeasuresforquality
control, and quality assurance according to GMP and
supplementaryguidelines.ThemanufactureofAIOadmix-
tures with a defined admixture sequence should be car-
riedoutasclosetothetimeofadministrationaspossible
because of stability problems. Defined in-process and
end-producttestsshouldbecarriedout,andthemainten-
ance of hygiene standards guaranteed. A standardised
and reproducible record of the complete manufacturing
processmustbedocumentedtoenableprecisetraceabil-
ity. The expiry dates are established through suitable,
validated laboratory tests. Suitable electronic support
and use of compounding machines are useful if a large
number of PN admixtures are being prepared.
Physico-chemical stability (assessment
and documentation)
• Physico-chemicalstabilityofanAIOadmixtureisessen-
tial for the safety and effectiveness of patient-specific
PN,anditsassurancerequiresspecialistpharmaceut-
ical knowledge (A).
• The stability should be documented for an application
period of 24 (–48) hours (C).
• Itissuitabletoselectandrestrictthenumberofdiffer-
ent PN regimes offered in each hospital (C).
Commentary
The large amounts of dissolved (reactive) components,
and the underlying disperse, meta-stable water-in-oil
emulsion system in an AIO PN admixture are reasons for
a high potential of incompatibility and instability. The
physico-chemical instabilities include:
• Lipid emulsion destabilisation (lipid droplet aggrega-
tion, lipid coalescence, creaming and breaking of the
emulsion) [31].
• The formation and precipitation of insoluble salts (i.e.
calcium monohydrogen phosphate) or complexation
and altered bioavailability of components (trace ele-
ments).
• Chemical changes or decomposition of components
(oxidation,reduction,hydrolysis)(vitamins,PUFA(lipid
peroxidation), amino acids), condensation (Maillard
reactions with amino acids and glucose).
• Adsorption,absorptionanddesorptionprocesseswith
the container material (insulin, vitamin A, diluents).
These reactions are time-dependant, dependant on the
concentration of reactants, pH-value, temperature, light
exposure,thepresenceofcatalyticallyactivecomponents
and the container material [17], [19], [23]. There are
differences in the composition and purity of the starting
materials of various providers, which are relevant for the
stability and potentially toxicity (e.g. aluminium), thus
making extrapolation of data extremely difficult [32].
Manufacturing processes have to be defined, qualified
and validated in order to get the necessary final product
quality(GMP).Apharmaceuticalassessment/document-
ation of the following factors is required for the ready-to-
use manufacture of a PN admixture:
• Defined starting materials
• Manufacturing procedures (admixture sequence)
• Lot-specific documents (process controls, process
conditions, involved staff)
• Suitable final product analyses like pH, concentration
testing of selected components etc.
• Stability-documented storage and application
guidelines (tests).
Problems can occur particularly in the stability (i.e. solu-
bilityofphosphateandcalciumsaltsorelectrolyte-related
destabilisation of lipid emulsion) of paediatric PN admix-
tures due to the relatively high contents of individual
components. Here it is helpful to use only binary, lipid-
free PN admixtures and organic phosphates or calcium
compounds. Solubility curves [19] or specific data for
emulsion destabilisation [32] are useful data for the de-
termination of compatible, and thus allowed electrolyte
dosages.
Simple methods are required for the documentation of
stability, considering time, expenses, equipment of a
hospital pharmacy, for example, using microscopic in-
stead of other methods in the testing of a lipid emulsion
[31], [32], [33].
Defined amino acids (glutamine, cysteine etc.) and oxy-
disablevitaminsandlipids(PUFA)arecriticalforchemical
stability. The presence of oxygen, catalysts (trace ele-
ments,light)andanti-oxidantshaveasignificantinfluence
on oxidative decomposition. Toxic and reactive products,
likefreeradicals,canbeformedintheprocessalongwith
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[34], [35] [36], [37].
Lipophilic compounds may result in interactions with the
container and administration materials. Plastic compon-
ents can be extracted (e.g. phthalates from PVC), or PN
components can be either absorbed or adsorbed [18].
The need to document the stability of PN admixtures
shows the necessity of selecting and restricting the
number of PN regimes and products available in a
hospital. This will enhance safety and effectiveness in
relationtophysico-chemicalstabilitydataovertheperiod
of storage and administration. These tasks require spe-
cificpharmaceuticalknowledgeandneedtobesupported
by (own) investigations.
Labelling
• PN admixtures prepared for individual patients must
be correctly labelled for reasons of drug safety (A).
Commentary
Complete labelling principally serves to prevent incorrect
administration and to provide controls prior to adminis-
tration.Itispartofthedocumentationprocess.Labelling,
therefore, should contain both the patient (name, date
of birth, body weight) and the product data. This com-
prises the following points:
• Date of manufacture
• Expiry date (storage period, administration period)
• Compositionincludingindicationofconcentrationand
daily dosage (in SI units)
• Energy and protein content
• Storage instructions
• Administration instructions
• Lot number
• Manufacturer
• Patient name and date for use
Standardised, printed labels are a useful and practical
solution.
Storage and transport
• Specifications for storage conditions must also be fol-
lowed during transport, and monitoring is required
where applicable (A).
Commentary
Admixtures should be protected from light and stored in
the fridge (2–8°C) for reasons of hygiene and stability.
If the admixture is lipid-free it can also be frozen. Cool
boxes are suitable as a means of transport [13], [17],
[19], [28].
Addition of micronutrients (trace
elements and vitamins)
• Micronutrients can be administered separately to AIO
admixtures since there is a lack of specific document-
ation regarding compatibility and stability (B), even
though micronutrients injected to the admixture in
home PN prior to administration are without identifi-
able adverse effects (C).
• Trace elements and/or combination preparations in-
cluding water-soluble or water-soluble/fat soluble
vitamin supplements can be added to PN admixtures
forPNcompatibilityandstabilityhasbeendocumented
(B).
• Considering micronutrient stability it can be stated:
Trace elements may be added to AIO admixtures in
the event of documented compatibility (B).
•
Fat-soluble vitamins formulated as lipid emulsion
areaddedtolipid-containingAIOadmixturesorlipid
infusions prior to administration (B).
•
• Micronutrients must be injected to admixtures under
strict asepsis, optimally and according to GMP using
a laminar airflow. Admixing should be restricted on
hospital wards for hygienic reasons (A). If this is not
possible due to, structural or organisational reasons,
this may be carried out according to pharmaceutical
guideline in individual cases, immediately before ad-
ministration,byspeciallytrainedmedico-pharmaceut-
ical staff. Medical prescription, pharmaceutically
documented stability and authorised ready-to-use
preparations(authorisedproductinformation)haveto
considered. The procedure to be followed should be
documentedinawrittenStandardOperatingProcedure
(C).
Commentary
Simultaneous administration of trace elements and
multivitamins in AIO admixtures is problematic due to
physico-chemicalreasons;itshowsincreaseddegradation
of oxidation-sensitive vitamins; (lipid) peroxidation is in-
creased. Trace elements and vitamins normally have a
high reactivity in the solution: some individual trace ele-
mentsshowcatalystfunctionsforchemicaldecomposition
reactions. Oxidation/reduction reactions can be further
intensifiedbylight(especiallyUVradiation),seeperoxide
formation [34], [35], [37], [38]. Therefore, the co-admin-
istration of multi vitamins and trace elements is not
generallyrecommended,evenifadministeredseparately
from AIO admixtures.
Micronutrients can inactivate each other (e.g. vitamin C
and ionised iron), can be inactivated by light (e.g. vitamin
K, A, B2) or absorbed into plastic (e.g. vitamin A). Degrad-
ation products form insoluble salts (e.g. Ca and oxalate
as a degradation product of vitamin C) [39], [40].
Trace elements should only be added to AIO admixtures
ifstabilityhasbeendocumented.Traceelementsolutions
show a strong acidic pH and represent in part polyvalent
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cations, which can greatly reduce the emulsion stability
[18], [31], [38] depending on their concentration.
Suitable concentrations of antioxidative vitamin supple-
ments (vitamin C and tocopherols) in an AIO admixture
help reduce lipid peroxidation [36], [41]. They have a
synergistic effect as chemical stabilisers of unsaturated
lipids in vitro.
Fat soluble vitamins (vitamins A, D, E, K) can be injected
into lipid-containing PN admixtures; lipid emulsion
provides light protection. Micellar-dissolved lipophile
vitamins can, according to manufacturer’s instructions,
also be administered in aqueous admixtures taking into
consideration stability and compatibility. If the daily-ap-
plied combination preparations of fat and water-soluble
vitamins do not contain vitamin K the weekly or even
monthly administration of vitamin K added to the lipids
in the AIO admixture is often still practice adequate in
adults and children [34]. To better control potential
osteoporosis a daily administration is recommended.
An example of a hospital guideline for the administration
of vitamins and trace element dosage in PN is cited here
(cf. chapter “Water, electrolytes, vitamins and trace ele-
ments” http://www.egms.de/en/gms/2009-
7/000080.shtml).
Ifnospecificdeficiencyispresent:incaseofPNproviding
>50% of daily energy requirements:
• Vitamins:
-Cernevit
®1vial(5ml)perdayasapiggybaginfusion
over 15–30 minutes or a slow 5-minute bolus at the
endoratthebeginningofthedailyPNadministration.
Cernevit
®canalsobeaddedtoPNduringmanufacture,
if compatible (light protection).
- Konakion MM
® vial 10 mg (diluted to 10 ml): doses
of 150 µg (150 µl of the dilution) added daily to the
AIO-PN
• Option:
- Vitalipid N Adult
® (A, D, E, K!) 1 vial (10 ml) per day
- Soluvit N Adult
® 1 vial (10 ml) per day
• Trace elements: Trace elements 1 vial (Spur-el KSA
®
10 ml) per day
Effects of adding electrolytes on the osmolarity of the
solution are shown in Table 1.
Micronutrientsarenotincludedincommerciallyavailable
multi-chamber bags because of their limited stability in
solution and their high risk of incompatibility. They must
be prescribed seperately, [17] and in a suitable dosage
for a PN regime. This mutual incompatibility usually re-
quires separate administration/admixture of trace ele-
mentsand(multi)vitamins,i.e.twoseparateintravenous
applications,oneforvitaminsandonefortraceelements.
The stability of vitamins is extremely limited in the pres-
ence of trace elements (vitamin C is decomposed within
hours in presence of catalytically active trace elements
like iron or copper and oxygen). That is why trace ele-
mentsandvitaminsarenotsuitableforcombinedadmin-
istration in admixtures (accelerated (catalysed) degrada-
tion of selected vitamins). Compatibility with the other
componentsintheAIOadmixturei.e.physicallipidstabil-
ity or chemical fatty acid stability (peroxidation) has to be
documented with the parenteral admixture even if
selected vitamins are compatible with trace elements,
especially fat-soluble and water-soluble vitamins with
sufficient degradation stability like pantothenic acid or
nicotinamide. The increased concentration of polyvalent
cations (iron, zinc) is cited as an example for the stability
of lipid emulsion or the influence of multi vitamins on
lipid peroxidation.
Light protection must be provided when micronutrients
inaqueoussolutionsareappliedasa(piggybag)infusion.
Lightprotectionwithoverwrapsmusthaveadocumented
and proven effectiveness [41], [42], [43]. Fat-soluble
vitamins, which are formulated as lipid emulsion, should
beaddedtoalipidemulsionoranAIOadmixturecontain-
ing lipids.
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AIO admixtures as vehicles for drugs
• AIO admixtures are usually not used as vehicles for
drugs due to the possibility of complex interactions. If
additions of drugs to the AIO admixture are required
as an exception, the stability and effectiveness must
be documented (B).
Commentary
Instabilitiesandphysico-chemicalincompatibilitiesoften
occur due to the many components of AIO admixtures
(lipid emulsion, amino acids, glucose, trace elements,
vitamins) [44], [45], [46]. New formulations, created in
emulsion systems with lipophilic drugs, show clinically
relevant differences in pharmacokinetics or changes in
bioavailability of the substrates as compared to the ori-
ginal product [47]. Incompatibilities due to pH changes,
redox reactions, complex formations, drug association
and solvolysis can also contribute to inactivation. Even if
some incompatibilities are recognised by precipitation,
colourings or gas formation, not all interactions can be
analysedinthismacroscopicmanner.Detailedinvestiga-
tionoranalysisanddocumentation,therefore,areessen-
tial before admixing.
Notes
This article is part of the publication of the Guidelines on
Parenteral Nutrition from the German Society for Nutri-
tional Medicine (overview and corresponding address
under http://www.egms.de/en/gms/2009-7/000086.
shtml).
English version edited by Sabine Verwied-Jorky, Rashmi
Mittal and Berthold Koletzko, Univ. of Munich Medical
Centre, Munich, Germany.
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